Cartesian Therapeutics (RNAC) EBT Margin: 2015-2025
Historic EBT Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -4,318.14%.
- Cartesian Therapeutics' EBT Margin fell 44166.00% to -4,318.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -7,674.79%, marking a year-over-year decrease of 723904.00%. This contributed to the annual value of -198.23% for FY2024, which is 71974.00% up from last year.
- Per Cartesian Therapeutics' latest filing, its EBT Margin stood at -4,318.14% for Q3 2025, which was up 35.86% from -6,732.55% recorded in Q2 2025.
- Cartesian Therapeutics' EBT Margin's 5-year high stood at 3,198.55% during Q4 2024, with a 5-year trough of -6,732.55% in Q2 2025.
- Its 3-year average for EBT Margin is -1,532.67%, with a median of -342.85% in 2023.
- In the last 5 years, Cartesian Therapeutics' EBT Margin tumbled by 807,882bps in 2021 and then spiked by 557,767bps in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' EBT Margin stood at 41.34% in 2021, then crashed by 797bps to 33.37% in 2022, then crashed by 241,249bps to -2,379.12% in 2023, then soared by 557,767bps to 3,198.55% in 2024, then plummeted by 44,166bps to -4,318.14% in 2025.
- Its EBT Margin stands at -4,318.14% for Q3 2025, versus -6,732.55% for Q2 2025 and -1,806.73% for Q1 2025.